Table 2.
Characteristics of MRD-positive patients and CAR-T cells
| Patient | Age, years | Sex | Maliganancy | Detection of MRD | MRD refractory/Relapse | No. of prior therapies | Last line of therapy | CAR-T cell infused/kg | Frequency of CAR-T infusion | MRD evaluation at 28th day after infusion | Additional therapy after CAR-T | CRS grade | Clinical outcomes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 46 | M | B-ALL Ph+ | FCM, BCR/ABL | Relapse | 8 | VDCLP | 5.84×106 | 1 | MR | Son/Haplo-HSCT(5/10) | 1 | MR |
| 2 | 13 | F | B-ALL | FCM | Refractory | 2 | CAMVL | 2.60×106 | 2 | MR | Consolidation& maintenance therapy | 0 | MR |
| 3 | 19 | M | B-ALL | FCM | Refractory | 2 | CAMVL | 2.37×106 | 2 | MR | Consolidation& maintenance therapy | 1 | MR |
| 4 | 17 | F | B-ALL | FCM | Relapse | 14 | VP | 5.57×106 | 3 | MR | No | 0 | Relapse |
| 5 | 27 | M | B-ALL | FCM | Refractory | 3 | FLAG | 6.98×106 | 1 | MR | Consolidation therapy&Consolidation therapy&Father /Haplo –HSCT (5/10) | 1 | Relapse |
| 6 | 40 | F | B-ALL Ph+ | FCM, BCR/ABL | Refractory | 3 | FLAG | 8.77×106 | 1 | MR | Daughter/Haplo -HSCT (5/10) | 1 | MR |
| 7 | 62 | M | B-ALL TET2 mutation | FCM, TET2 | Relapse | 10 | VDCP | 7.13×106 | 3 | MR | No | 1 | Relapse |
| 8 | 41 | F | B-ALL | FCM | Relapse | 11 | VMMP | 6.57×106 | 1 | MR | No | 1 | MR |
| 9 | 17 | M | B-ALL | FCM | Refractory | 2 | CAMVL | 9.22×106 | 3 | MR | Consolidation therapy | 1 | Relapse (death) |
| 10 | 42 | F | B-ALL Ph+, TP53+ , C-kit+ | FCM, BCR/ABL, TP53 | Refractory | 4 | VMCP + Imatinib | 9.25×106 | 1 | MR | Sibling HSCT | 0 | MR |
| 11 | 29 | M | B-ALL IKZF1 + | FCM, IKZF1 | Refractory | 4 | EOACP | 10.4×106 | 1 | No response | Father /Haplo -HSCT (5/10) | 1 | MR |
| 12 | 45 | F | B-ALL Ph+ , IKZF1 + | FCM, BCR/ABL, IKZF1 | Refractory | 5 | VTCD + Dasatinib | 8.77×106 | 1 | No response | Sibling HSCT | 1 | MR |
| 13 | 38 | M | B-ALL | FCM | Relapse | 8 | VDLD | 2.2×106 | 1 | MR | No | 1 | MR |
| 14 | 37 | F | B-ALL Ph+ | FCM, BCR/ABL | Relapse | 8 | VDCP + Dasatinib | 3.1×106 | 1 | MR | Sibling HSCT | 0 | MR |
F female, M male, No. number, Haplo-HSCT haploidentical hematopoietic stem cell transplantation, MR molecular remission. VP vincristine+ dexamethasone, CAMVL cyclophosphamide+ cytarabine+ 6-mereaptopurine+ vincristine/vindesine+ L-asparaginase, FLAG fludarabine+ cytarabine+ granulocyte colony-stimulating factor, VDCP vincristine/vindesine + daunorubicin+ cyclophosphamide + dexamethasone, VMMP vincristine/vindesine+ prednison+ 6-mereaptopurine+ methotrexate, VMCP vincristine/vindesine+ mitoxantrone+ Ifosfamide+ prednison, EOACP VP-16+ vincristine+ cytarabine+ cyclophosphamide+ prednison, VTCD vincristine+ VM-26 +cyclophosphamide+ dexamethasone, VDLD vincristine/vindesine + daunorubicin+ L-asparaginase+ dexamethasone